程序性细胞死亡配体 1 (PD-L1) 表达是头颈鳞状细胞癌中免疫检查点抑制剂反应的预测生物标志物。鉴于用于 PD-L1 检测的抗体和平台的范围，了解不同染色和评分方法的性能至关重要。使用 106 个组织微阵列 (TMA) 核心和 50 个完整切片评估牙山医疗中心 156 例头颈粘膜鳞状细胞癌 (HNmSCC) 病例中的 PD-L1 表达。对三种标准化 PD-L1 检测（22C3 pharmDx、SP263 和 28-8 pharmDx）和一种实验室开发的检测（22C3 LDT）进行了评估：综合阳性评分 (CPS) ≥1、≥20 和 ≥50以及肿瘤阳性评分（TPS）≥1%、≥20%、≥50% 的截止值。对于 CPS [组内相关系数 (ICC) 范围 0.73-0.94] 和 TPS（ICC 范围 0.70-0.94）以及 TMA 和整个切片队列，测定之间连续尺度的一致性为良好到优秀。根据 Gwet 的 AC1 分析，通过可变截断值进行分层表明大多数分析之间具有中等至良好的一致性。使用 22C3 pharmDx 检测，PD-L1 表达与肿瘤位置显着相关（CPS，p=0.014；TPS，p=0.033）。 PD-L1 检测之间存在显着的一致性，表明它们在 HNmSCC 中具有潜在的互换性。版权所有 © 2024 澳大利亚皇家病理学家学院。由 Elsevier B.V. 出版。保留所有权利。

Programmed cell death-ligand 1 (PD-L1) expression is a predictive biomarker for response to immune checkpoint inhibitor in head and neck squamous cell carcinoma. Given the range of antibodies and platforms for PD-L1 testing, it is essential to understand the performance of different staining and scoring methods. PD-L1 expression in 156 head and neck mucosal squamous cell carcinoma (HNmSCC) cases at Asan Medical Center was assessed using 106 tissue microarray (TMA) cores and 50 whole slides. Three standardised PD-L1 assays (22C3 pharmDx, SP263, and 28-8 pharmDx) and one laboratory-developed test (22C3 LDT) were evaluated: the combined positive score (CPS) with ≥1, ≥20, and ≥50 cut-offs, and the tumour positive score (TPS) with ≥1%, ≥20%, ≥50% cut-offs. Concordance on a continuous scale among the assays was good to excellent for CPS [intraclass correlation coefficient (ICC) range 0.73-0.94] and TPS (ICC range 0.70-0.94) and in both TMA and whole slides cohorts. Stratification by variable cut-offs demonstrated moderate to good agreement among most assays, as analysed by Gwet's AC1. PD-L1 expression was significantly correlated with tumour location using the 22C3 pharmDx assay (CPS, p=0.014; TPS, p=0.033). Notable concordance was found among PD-L1 assays, suggesting their potential interchangeability in HNmSCC.Copyright © 2024 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.